Literature DB >> 17915803

Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin.

Pritam Kanagale1, Braj Bhushan Lohray, Ambikanandan Misra, Prakash Davadra, Rajesh Kini.   

Abstract

The aim of the current study was to design a porous osmotic pump-based drug delivery system for controlled release of oxybutynin. The porous osmotic pump contains pore-forming water-soluble additives in the coating membrane, which after coming in contact with water, dissolve, resulting in an in situ formation of a microporous structure. The dosage regimen of oxybutynin is one 5-mg tablet 2 to 3 times a day. The plasma half-life ranges from approximately 2 to 3 hours. Hence, oxybutynin was chosen as a model drug with an aim to develop a controlled release system for a period of 24 hours. Linear and reproducible release similar to that of Ditropan XL was achieved for optimized formulation (f2 >50) independent of hydrodynamic conditions. The effect of different formulation variables, namely, ratio of drug to osmogent, membrane weight gain, and level of pore former on the in vitro release was studied. Cellulose acetate (CA) was used as the semipermeable membrane. It was found that drug release rate increased with the amount of osmogent because of the increased water uptake, and hence increased driving force for drug release. Oxybutynin release was inversely proportional to the membrane weight gain; however, directly related to the level of pore former, sorbitol, in the membrane. This system was found to deliver oxybutynin at a zero-order rate for 20 hours. The effect of pH on drug release was also studied. The optimized formulations were subjected to stability studies as per International Conference on Harmonisation (ICH) guidelines and formulations were stable after a 3 month study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17915803      PMCID: PMC2750549          DOI: 10.1208/pt0803053

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  6 in total

1.  Elementary osmotic pump.

Authors:  F Theeuwes
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

Review 2.  Chemical reactivity in solid-state pharmaceuticals: formulation implications.

Authors:  S R Byrn; W Xu; A W Newman
Journal:  Adv Drug Deliv Rev       Date:  2001-05-16       Impact factor: 15.470

Review 3.  An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.

Authors:  M M Goldenberg
Journal:  Clin Ther       Date:  1999-04       Impact factor: 3.393

4.  Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.

Authors:  S K Gupta; G Sathyan
Journal:  J Clin Pharmacol       Date:  1999-03       Impact factor: 3.126

5.  The pharmacokinetics of oxybutynin in man.

Authors:  J Douchamps; F Derenne; A Stockis; D Gangji; M Juvent; A Herchuelz
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology.

Authors:  Rajan K Verma; Aditya M Kaushal; Sanjay Garg
Journal:  Int J Pharm       Date:  2003-09-16       Impact factor: 5.875

  6 in total
  3 in total

1.  Development and in vitro/in vivo evaluation of etodolac controlled porosity osmotic pump tablets.

Authors:  Ahmed Abd-Elbary; Mina Ibrahim Tadros; Ahmed Adel Alaa-Eldin
Journal:  AAPS PharmSciTech       Date:  2011-04-09       Impact factor: 3.246

2.  Development and optimization of buspirone oral osmotic pump tablet.

Authors:  K Derakhshandeh; M Ghasemnejad Berenji
Journal:  Res Pharm Sci       Date:  2014 Jul-Aug

3.  Formulation and evaluation of controlled porosity osmotic pump for oral delivery of ketorolac.

Authors:  Fatima Sanjeri Dasankoppa; Mahesh Ningangowdar; Hasanpasha Sholapur
Journal:  J Basic Clin Pharm       Date:  2012-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.